ijerph-logo

Journal Browser

Journal Browser

Advances in Public Health: Management of Technology and Innovation for Challenges and Opportunities of Pharmaceutical Industry

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Public Health Statistics and Risk Assessment".

Deadline for manuscript submissions: closed (12 April 2023) | Viewed by 11618

Special Issue Editor

Graduate School of Technology Management, Ritsumeikan University, Osaka 567-8570, Japan
Interests: technology management; innovation management; pharmaceutical industry; public health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The pharmaceutical industry plays a significant role in the research, development, production, and distribution of medications to reduce the incidence of diseases, to treat diseases and enhance the quality of life of people. The industry is expected not only to contribute to technological advancements through cutting-edge research but also to ensure lasting innovations complying with laws, regulations, and industry standards to meet the healthcare demands of populations. Sustainable growth and development of the pharmaceutical industry and related ecosystems are becoming global agendas and include complex and wide-ranging issues and goals for the strategic and economic success. Management of technology and innovation is one of the ways for achievement of growth and development of the industry and for resolution of conflicts amongst different goals and stakeholders. However, our expertise in management of technology and innovation is still at a nascent stage to meet expectations and to realize further growth and development of the industry.

This Special Issue covers a wide range of topics on management of technology and innovation toward the challenges and opportunities for growth and development of the pharmaceutical industry. It will include but is not limited to:

  • Conceptual propositions on management of technology and innovation in the pharmaceutical industry;
  • Systematic reviews on management of technology and innovation in the pharmaceutical industry;
  • Methodology for the analysis, design, and implementation of innovative technology, products/services, and systems to realize growth and development of the pharmaceutical industry;
  • Practices and case studies on management of technology and innovation for growth and development of the pharmaceutical industry.

We invite papers that comprehensively examine the current status based on credible analysis and evidence and also provide potential solutions with salient ideas and future perspectives with profound insights and normative perspectives. We appreciate papers dealing with specific topics from interdisciplinary and transdisciplinary approaches. We also welcome papers with both qualitative and quantitative approaches. We expect that this Special Issue will serve as a forum for anyone with an interest in and passion toward the realization of growth and development of the pharmaceutical industry through technology and innovation

Dr. Kota Kodama
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmaceutical industry
  • healthcare ecosystem
  • advantageous strategy
  • economic impact
  • management issues
  • technology and innovation management
  • science, technology, and innovation policy
  • methods and tools for technology and innovation
  • case studies and action research

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 632 KiB  
Article
A Framework and System Design for Medicines Resources Allocation: A Multi-Stakeholder Assessment of Processes and Electronic Platform Needs
by Abdullah Alanazi, Ibtihal Alshatri and Bakheet Aldosari
Int. J. Environ. Res. Public Health 2023, 20(5), 3846; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph20053846 - 21 Feb 2023
Cited by 1 | Viewed by 1365
Abstract
Utilizing resources effectively is becoming more critical, especially with the ever-increasing healthcare cost. Little is known about the current practices used by healthcare organizations for the procurement, allocation, and utilization of medical resources. Moreover, the available literature needed to be enriched to bridge [...] Read more.
Utilizing resources effectively is becoming more critical, especially with the ever-increasing healthcare cost. Little is known about the current practices used by healthcare organizations for the procurement, allocation, and utilization of medical resources. Moreover, the available literature needed to be enriched to bridge the link between resource utilization and allocation processes’ performance and outcomes. This study investigated the processes that major healthcare facilities in Saudi Arabia apply to procure, allocate and utilize medicines resources. The work explored the role of electronic systems and provided a system design and conceptual framework to enhance the availability and utilization of resources. A three-part multi-method, multi-field (healthcare and operational), and multi-level exploratory and descriptive qualitative research design were used to collect the data that was analyzed and interrupted to feed the “future state” model. The findings demonstrated the current state procedure and discussed the challenges and the experts’ opinions on developing the framework. The framework includes various elements and perspectives and is designed based on the results of the first part and was further validated by experts who were optimistic about the inclusiveness of this framework. Some major technical, operational, and human factors were perceived as obstacles by the subjects. Decision-makers can adopt the conceptual framework to gain insights into interrelated objects, entities, and processes. The findings of this study can imply future directions for research and practices. Full article
Show Figures

Figure 1

13 pages, 854 KiB  
Article
Willingness to Pay for Implementation of an Environmentally Friendly Pharmaceutical Policy in Finland—A Discrete Choice Experiment Study
by Lasse Alajärvi, Aku-Ville Lehtimäki, Johanna Timonen and Janne Martikainen
Int. J. Environ. Res. Public Health 2022, 19(11), 6535; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph19116535 - 27 May 2022
Cited by 6 | Viewed by 2427
Abstract
The use of pharmaceuticals is their main pathway to the environment, making the public a major stakeholder in environmentally friendly pharmaceutical policies, including an environmental classification system for medicines. We studied the Finnish adult population’s (n = 2030) preferences and willingness to [...] Read more.
The use of pharmaceuticals is their main pathway to the environment, making the public a major stakeholder in environmentally friendly pharmaceutical policies, including an environmental classification system for medicines. We studied the Finnish adult population’s (n = 2030) preferences and willingness to pay (WTP) for an environmentally friendly pharmaceutical policy by means of an online survey employing a discrete choice experiment (DCE). We also studied the relative importance of the policy attributes, namely, the environmental impact, geographical scope, available information about the environmental impact of a pharmaceutical, and the effect of the respondents’ general environmental attitudes on the WTP. The total annual WTP of the Finnish adult population ranges from 37 million to 134 million euros, depending on the attribute levels. Moreover, the environmental attitude of a respondent had a significant impact on the WTP. Generally, the environmental impact of the policy was the most important attribute, the geographical scope of the policy the second, and information about the environmental impact of pharmaceuticals was the third most important attribute. However, the most environmentally friendly respondents preferred information as the second important attribute. This study provides insights into the environmental valuations of the public to be used in preparing new pharmaceutical policy measures. Full article
Show Figures

Figure 1

15 pages, 3915 KiB  
Article
A Layered Adopter-Structure Model for the Download of COVID-19 Contact Tracing Apps: A System Dynamics Study for mHealth Penetration
by Makoto Niwa, Yeongjoo Lim, Shintaro Sengoku and Kota Kodama
Int. J. Environ. Res. Public Health 2022, 19(7), 4331; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph19074331 - 04 Apr 2022
Viewed by 1771
Abstract
(1) Background: Contact tracing and notification apps for coronavirus disease 2019 (COVID-19) are installed on smartphones and are intended to detect contact with another person’s device. A high installation rate is important for these apps to enable them to be effective countermeasures against [...] Read more.
(1) Background: Contact tracing and notification apps for coronavirus disease 2019 (COVID-19) are installed on smartphones and are intended to detect contact with another person’s device. A high installation rate is important for these apps to enable them to be effective countermeasures against the silent transmission of diseases. However, the installation rate varies among apps and regions and the penetration dynamics of these applications are unclear. (2) Methods: The download behavior of contact tracing applications was investigated using publicly available datasets. The increase in downloads was modeled using a system dynamics model derived from the product growth model. (3) Results: The imitation effects present in the traditional product growth model were not observed in COVID-19 contact tracing apps. The system dynamics model, without the imitation effect, identified the downloads of the Australian COVIDSafe app. The system dynamics model, with a layered adopter, identified the downloads of the Japanese tracing app COCOA. The spread of COVID-19 and overall anti-COVID-19 government intervention measures in response to the spread of infection seemed to result in an increase in downloads. (4) Discussion: The suggested layered structure of users implied that individualized promotion for each layer was important. Addressing the issues among users who are skeptical about adoption is pertinent for optimal penetration of the apps. Full article
Show Figures

Figure 1

18 pages, 2015 KiB  
Article
Evolutionary Path and Innovative Development of Pharmaceutical Industrial Cluster—A Case Study of Shijiazhuang, China
by Liping Fu, Fan Wu and Shan Zhang
Int. J. Environ. Res. Public Health 2022, 19(5), 2928; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph19052928 - 02 Mar 2022
Cited by 2 | Viewed by 2603
Abstract
The innovation and development practices of the pharmaceutical industry are of great importance for the continual enhancement of public health. Industrial clusters are one of the important means by which the pharmaceutical industry can be transformed and developed, but there is a lack [...] Read more.
The innovation and development practices of the pharmaceutical industry are of great importance for the continual enhancement of public health. Industrial clusters are one of the important means by which the pharmaceutical industry can be transformed and developed, but there is a lack of research on the evolutionary path and development innovation of pharmaceutical industrial clusters. As a country with a major pharmaceutical industry, the transformation and development path of traditional pharmaceutical industrial clusters in China has important reference value for the sustainable development of the global pharmaceutical industry. Through an analysis of the evolution of traditional pharmaceutical industrial clusters in Shijiazhuang, this study explores the law of the dynamic evolution of pharmaceutical industrial clusters and the associated mechanisms. Specifically, we conclude that the evolutionary path of traditional pharmaceutical industrial clusters can be divided into the government-led pharmaceutical industrial cluster start-up stage, the government-guided pharmaceutical industrial cluster development stage, and the government-served pharmaceutical industrial cluster transformation stage. The operating mechanisms include a self-organization mechanism, an innovation-driven mechanism, and an outward associated mechanism, each of which plays different roles in the different stages of the dynamic evolution of the cluster, and the synergistic operation of the three mechanisms forms an important basis for the evolution of pharmaceutical industrial clusters. We found that the innovation development of traditional pharmaceutical industrial clusters is influenced by the synergy of the self-organization, innovation-driven, and outward associated mechanisms. The self-organization mechanism is a necessary condition for pharmaceutical industrial clusters to realize the transition from disorder to order. The innovation-driven mechanism is the core driving force for the innovative development of pharmaceutical industrial clusters. Finally, the outward associated mechanism is the main means by which pharmaceutical industrial clusters integrate into the global value chain. Full article
Show Figures

Figure 1

14 pages, 1390 KiB  
Article
The Impact of Compensation Gap on Corporate Innovation: Evidence from China’s Pharmaceutical Industry
by Liping Fu, Shan Zhang and Fan Wu
Int. J. Environ. Res. Public Health 2022, 19(3), 1756; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph19031756 - 03 Feb 2022
Cited by 4 | Viewed by 2001
Abstract
The pharmaceutical industry is typically driven by innovation, and is relevant to people’s livelihoods. How to effectively motivate pharmaceutical enterprises to engage in innovative activities is a hot topic. On the basis of the perspective of the combined effect of tournament theory and [...] Read more.
The pharmaceutical industry is typically driven by innovation, and is relevant to people’s livelihoods. How to effectively motivate pharmaceutical enterprises to engage in innovative activities is a hot topic. On the basis of the perspective of the combined effect of tournament theory and social comparison theory, this study explored the impact of internal compensation gap on corporate innovation by using data from China’s listed pharmaceutical enterprises during 2011–2018. The findings show a nonlinear (inverted-U-shaped) relationship between compensation gap and corporate innovation within the pharmaceutical industry, which illustrates that the role of the compensation gap is not endless. We also find the optimal compensation gap between executives and employees. Further analyses indicate that this association is more pronounced in regions with low marketization levels, and in large enterprises. Moreover, the practical significance of the results is explored with an expectation of providing theoretical references for the pharmaceutical industry to establish reasonable incentive mechanisms and promote innovative development, and for the government to introduce innovation incentive policies. Full article
Show Figures

Figure 1

Back to TopTop